26 February 2024 in Breast Cancer Research and Treatment
Purpose: Follow-up guidelines barely diverge from a one-size-fits-all approach, even though the risk of recurrence differs per patient. However, the personalization of breast cancer care improves outcomes for patients. This study explores the variation in follow-up pathways in the Netherlands using real-world data to determine guideline adherence and the gap between daily practice and risk-based surveillance, to demonstrate the benefits of personalized risk-based surveillance compared with usual care. Methods: Patients with stage I–III invasive breast cancer who received surgical treatment in a general hospital between 2005 and 2020 were selected from the Netherlands Cancer Registry and included all imaging activities during follow-up from hospital-based electronic health records. Process analysis techniques were used to map patients and activities to investigate the real-world utilisation of resources and identify the opportunities for improvement. The INFLUENCE 2.0 nomogram was used for risk prediction of recurrence. Results: In the period between 2005 and 2020, 3478 patients were included with a mean follow-up of 4.9 years. In the first 12 months following treatment, patients visited the hospital between 1 and 5 times (mean 1.3, IQR 1–1) and received between 1 and 9 imaging activities (mean 1.7, IQR 1–2). Mammogram was the prevailing imaging modality, accounting for 70% of imaging activities. Patients with a low predicted risk of recurrence visited the hospital more often. Conclusions: Deviations from the guideline were not in line with the risk of recurrence and revealed a large gap, indicating that it is hard for clinicians to accurately estimate this risk and therefore objective risk predictions could bridge this gap.
21 November 2025 in Computers in Biology and Medicine
Deep learning can mitigate the global radiologist shortage but its development requires large-scale annotated datasets. This study introduces SCALE (Scalable Clinical Annotation with Location Evidence), a fully automated method for generating voxel-level annotations. It uses location priors that are automatically extracted from medical reports, tracked biopsy coordinates, or provided anatomical sectors. We annotated a large-scale dataset comprising 17 896 cases from 16 562 patients across 24 hospitals in 10 countries and 2 continents, using both SCALE and a count-based weakly semisupervised learning (CWSSL) method. An optimized algorithm was developed and trained on these datasets. Evaluation with 1561 cases from 1561 patients across 19 hospitals in 3 countries and 1 continent showed the superiority of the model trained on the dataset with SCALE annotations, achieving a case-level area under the receiver operating characteristic curve of 0.856. This is +0.012 compared to supervised learning (p=0.02), +0.007 compared to training with CWSSL (p=0.12), and +0.006 compared to the Prostate Imaging: Cancer AI (PI-CAI) Ensemble AI System. These results demonstrate that automated, location-guided annotation enables scalable development of AI for clinically significant prostate cancer detection on MRI, surpassing previous methods, and paving the way for broader clinical deployment.